An academic metabolic lab qualified a six-member GLP-1/incretin reference panel for a comparative receptor study
A university metabolic-research group needed a matched set of incretin reference standards — mono-, dual-, and tri-agonists — characterized to the same depth so a cross-receptor comparison could not be questioned on identity grounds. A single qualification campaign with harmonised per-lot packets cleared the panel for the study.
Published May 26, 2026 · Anonymized research-buyer story
Incretin SKUs qualified as a panel
6
Documentation depth
Harmonised per-lot template
Counter-ion form
Acetate · residual TFA reported
Sequence verification
First lot, each investigational standard
Challenge
The group's Principal Investigator was designing a comparative in vitro receptor-pharmacology study spanning the incretin progression — a GLP-1 mono-agonist, two GLP-1/glucagon dual agonists, and a GIP/GLP-1/glucagon tri-agonist — read side by side in the same assay system. The methodological problem was matched-depth identity: a cross-receptor comparison is only defensible if every standard in the panel was characterized to the same level, and several of the molecules are investigational, so an intact-mass figure alone left more identity ambiguity than a comparative study could carry. The previous practice of buying each standard from whichever supplier had stock meant inconsistent analytical packets and salt forms across the panel, which a reviewer could flag as a confound. The PI needed one supplier to qualify the whole panel with harmonised documentation and a uniform acetate-salt, low-TFA form suitable for the cell-based readout.
Approach
Lyochem scoped the panel as a single qualification campaign across the six SKUs the group identified, releasing each lot to the same packet template: RP-HPLC purity at 214 nm with the chromatogram, ESI-MS identity against the theoretical mass for the supplied form, water content by Karl Fischer, and acetate counter-ion with residual TFA reported as a number. For the investigational dual- and tri-agonists, each first lot carried an LC-MS/MS b/y-ion read so residue order and modification placement were documented rather than inferred from mass, and the per-lot COA reported the batch-specific formula and salt mass for the dosing calculation. The group's own QC cross-checked the harmonised packets against the labelled sequences before the comparative assay opened.
Outcome
The full panel cleared the lab's qualification within a few weeks of first shipment, with every standard carrying the same documentation depth and salt form. The comparative receptor study proceeded on a matched-identity basis, and the group's resulting manuscript cited Lyochem as the reference-standard source together with the per-lot sequence-verification and counter-ion figures the journal's methods section treated as a required disclosure for an investigational-compound comparison.
“For a cross-receptor comparison, matched-depth identity across the whole panel was the methodological linchpin — a tri-agonist confirmed only by intact mass next to a mono-agonist confirmed by sequence would have been a reviewer's first question. Getting every standard to the same packet template, same salt form, was exactly what the comparison needed to stand.”